Last reviewed · How we verify
tOPV
At a glance
| Generic name | tOPV |
|---|---|
| Sponsor | University of Virginia |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation (PHASE2)
- Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh (PHASE2)
- Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (PHASE3)
- Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines (PHASE1)
- Evaluation of an IgG Deficiency Rapid Screening Test: A Performance Study With Primary Immunodeficiency (PID) Patients in Tunisia
- Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines (PHASE1, PHASE2)
- Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in Bangladesh (PHASE3)
- Immunogenicity of Different Primary Immunization Schedules with Inactivated Poliovirus Vaccine (IPV) Plus Pentavalent Vaccine (DTwP-HBV-Hib) or with Hexavalent Vaccine (DTwP-HBV-Hib-IPV) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tOPV CI brief — competitive landscape report
- tOPV updates RSS · CI watch RSS
- University of Virginia portfolio CI